非小细胞肺癌中K-RAS基因突变最新临床意义

基础医学与临床 ›› 2010, Vol. 30 ›› Issue (2): 212-214.

非小细胞肺癌中K-RAS基因突变最新临床意义

付鲜花黄建瑾

浙江大学医学院附属第二医院

收稿日期:2009-03-10 修回日期:2009-04-29 出版日期:2010-02-05 发布日期:2010-02-05

Research progresses on K-RAS mutation of non-small cell lung cancer

Xian-hua FU, Jian-jin HUANG

The Affiliated Second Hospital, School of Medicine, Zhejiang University

Received:2009-03-10 Revised:2009-04-29 Online:2010-02-05 Published:2010-02-05

摘要/Abstract

摘要： 非小细胞肺癌（NCSLC）中15-30%有K-RAS突变，目前研究认为，其突变与表皮生长因子受体(EGFR)突变互相排斥，与EGFR酪氨酸激酶抑制剂(EGFR-TKIs)耐药正相关，但与C-225疗效无正相关关系，与NCSLC不良预后有关。现有许多研究探索法尼基转移酶抑制剂（Ftase抑制剂,FTIs）、RAF抑制剂、MAPK激酶（MEK）抑制剂来消除突变性K-RAS活性，改善临床疗效。

关键词: K-RAS, 非小细胞肺癌

Abstract: Mutated K-RAS can been observed among 15-30% NSCLC patients,the mutations of K-RAS and EGFR are mutually exclusive,K-RAS mutations have poor sensitivity to EGFR-TKIs,The response of C-225 is not restricted to mutated K-RAS , NSCLC patients with K-RAS mutations are associated with unfavorable prognosis.A number of different approaches such as Ftase inhibitors,RAF inhibitors,MEK inhibitors aimed at abrogating K-RAS activity to improve clinical response have been explored in clinical trials.

Key words: K-RAS, non-small cell cancer

中图分类号:

付鲜花黄建瑾. 非小细胞肺癌中K-RAS基因突变最新临床意义[J]. 基础医学与临床, 2010, 30(2): 212-214.

Xian-hua FU; Jian-jin HUANG. Research progresses on K-RAS mutation of non-small cell lung cancer[J]. Basic & Clinical Medicine, 2010, 30(2): 212-214.

[1]	欧洁王顺超孙丽丹曹春雨吴红艳. 鸟氨酸脱羧酶抗酶-1过表达促进非小细胞肺癌细胞系A549凋亡[J]. 基础医学与临床, 2019, 39(3): 332-336.
[2]	赵鹏郑贸根程光王国臣侯静朴李作生. LOX与HIF-1α在非小细胞肺癌中表达增强[J]. 基础医学与临床, 2015, 35(6): 776-780.
[3]	唐敏武晓楠程刚. Crizotinib在ALK基因阳性非小细胞肺癌中的临床研究进展[J]. 基础医学与临床, 2013, 33(3): 382-386.
[4]	张士化卢凯华王庆苓侯亚义. 非小细胞肺癌组织中Midkine蛋白表达上调[J]. 基础医学与临床, 2009, 29(2): 201-203.
[5]	叶韵斌陈玲佘志廉陈慧菁蔡丹柳硕岩陈强. SELDI-TOF-MS技术筛选NSCLC血清肿瘤标志物[J]. 基础医学与临床, 2009, 29(11): 1174-1179.